Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
The healthcare sector is not homogeneous and includes many different industries ranging from managed care organizations, healthcare facilities providers, medical device manufacturers through to biotech and traditional pharmaceutical companies. Investors in heathcare therefore should remain mindful of the different drivers and appropriate metrics associated with the various sub-sectors.
That said, and recent market volatility aside, long-term growth of the healthcare sector overall continues to be fueled by the aging of the population and decisions in Congress related to government funding. Changes to healthcare policy remain an important signpost to investing in the sector.
President-elect Obama's pledge to address the issue of universal healthcare, coupled with the recent appointment of Tom Daschle to the position of Secretary of Health and Human Services and the commencement of information gathering meetings at the regional level, suggest healthcare reform initiatives will most likely be executed sooner rather than later. Funding for the State Children's Health Insurance Program (SCHIP) is likely to be one of the first of the health care issues addressed by Congress during 1Q09.
Despite references by Democratic senators to target reimbursement levels paid to insurers that operate Medicare Advantage plans, we believe managed care overall will continue to play a central role in the distribution of healthcare services and an important sub-sector of healthcare for investors. Furthermore, health plans could benefit from any efforts to reduce the number of uninsured.
Nonetheless, we believe further weakening of the economy would most likely exacerbate the already high level of uninsured in the population in the short term, which in turn will negatively impact other healthcare sub-sectors such as hospitals, and add to already significant levels of bad debt.
OPPORTUNITIES
Despite our currently neutral stance on managed care providers overall, we continue to rate Wellpoint ( WLP - Analyst Report ) as a Buy given its broad product offering, geographic reach and potential for added synergy gains from relatively recent acquisitions. Furthermore, managed care companies in general remain well-capitalized and unlikely to be affected by the current credit crisis, negative investor sentiment aside.
Humana ( HUM - Analyst Report ) also remains attractive at current levels. The company is one of the largest healthcare plan providers in the United States, with approval from The Centers for Medicare & Medicaid Services (CMS) to offer the Medicare Part D prescription drug plans (PDP) to the more than 42 million Medicare-eligible beneficiaries.
WEAKNESSES
Highly leveraged companies are obviously more likely to be affected by any deterioration of the current credit crisis. For example, Healthsouth ( HLS - Snapshot Report ) , which, despite efforts to reduce debt exposure, remains vulnerable.
Read the full reports :
Analyst Report on WLP
Analyst Report on HUM
Snapshot Report on HLS